SEC Filings
FDA Grants HUTCHMED's Sovleplenib Second Orphan Status, This Time for AIHA
The FDA status carries 7 years of US market exclusivity if the oral drug is approved, and HUTCHMED keeps all worldwide rights.
HUTCHMED (China) (HCM) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
SEC Filings
The FDA status carries 7 years of US market exclusivity if the oral drug is approved, and HUTCHMED keeps all worldwide rights.
SEC Filings
The oral Syk inhibitor targets primary immune thrombocytopenia, while China regulators review two applications for the drug.